What question did this study set out to answer?

To evaluate the efficacy of low-dose daratumumab combined with rituximab in achieving remission in refractory autoimmune cytopenias.

July 10, 2026Annals of HematologyOpen Access

Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study shows enhanced response rates in treatment-refractory autoimmune cytopenias, suggesting new therapeutic options.

To evaluate the efficacy of low-dose daratumumab combined with rituximab in achieving remission in refractory autoimmune cytopenias.
Conducted a retrospective cohort study with 22 adults receiving low-dose daratumumab and rituximab.
Main endpoints included overall response rate, complete response rate, relapse-free survival, and safety.
Participants received daratumumab (100 mg) and rituximab (100 mg weekly for 4 doses) with glucocorticoids.
Initial response achieved in 95.5% of participants (CRR 27.3%, partial response 68.2%).
Sustained overall response rate at 81.8% with a complete response rate of 59.1% during 322 days of follow-up.
Averse events occurred in 36.4% of patients, primarily infections and rash, all resolved with intervention.

Long et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study shows enhanced response rates in treatment-refractory autoimmune cytopenias, suggesting new therapeutic options.